Second and third TNF inhibitors in European patients with axial spondyloarthritis : effectiveness and impact of the reason for switching
Objective: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with (i) treatment line (second and third TNFi-series) and (ii) reason for withdrawal from the preceding TNFi [lack of efficacy (LOE) vs adverse events (AE)]. Methods: Prospectively collected routine care data from 12 European registries